Evaluation of an immunochromatography-based rapid antigen test, Inspecter Kowa® SARS-CoV-2, using saliva specimens for the detection of SARS-CoV-2
Copyright © 2023 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights reserved..
BACKGROUND: In the context of the coronavirus disease 2019 (COVID-19) pandemic, a rapid and reliable point-of-care test is an essential tool for controlling the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In particular, an immunochromatography test (ICT) that uses saliva specimens for rapid antigen detection not only reduces the risk of secondary infections but also reduces the burden on medical personnel.
METHODS: The newly developed salivary antigen test kit "Inspecter Kowa® SARS-CoV-2" is an ICT to which saliva specimens can be directly applied. We evaluated its usefulness in comparison with reverse transcription quantitative PCR (RT-qPCR) and the Espline® SARS-CoV-2 Kit for the detection of SARS-CoV-2 using nasopharyngeal swab specimens. In this study, 140 patients with suspected symptomatic COVID-19 who visited our hospital were enrolled, and nasopharyngeal swab and saliva specimens were collected after they consented to participate in the study.
RESULTS: Inspector Kowa SARS-CoV-2 was positive in 45 of 61 (73.8%) saliva that were positive by RT-qPCR and the Espline® SARS-CoV-2 Kit was also positive in 56 of 60 (93.3%) Np swabs that were positive by RT-qPCR. Good antigen detection was achieved by ICT with saliva and nasopharyngeal swab specimens when viral load was ≥105 copies/mL, whereas detection sensitivity was low when viral load was <105 copies/mL, especially in saliva specimens.
CONCLUSION: This ICT for the detection of SARS-CoV-2 salivary antigen is an attractive tool that does not require specialized equipment and allows patients to perform the entire process from sample collection to self-diagnose and to reduce the burden on medical care during a pandemic.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy - 29(2023), 6 vom: 01. Juni, Seite 586-591 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kodana, Masahiro [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antigen detection |
|---|
| Anmerkungen: |
Date Completed 18.04.2023 Date Revised 18.04.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jiac.2023.02.011 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353551902 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353551902 | ||
| 003 | DE-627 | ||
| 005 | 20231226060250.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jiac.2023.02.011 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1178.xml |
| 035 | |a (DE-627)NLM353551902 | ||
| 035 | |a (NLM)36849098 | ||
| 035 | |a (PII)S1341-321X(23)00047-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kodana, Masahiro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of an immunochromatography-based rapid antigen test, Inspecter Kowa® SARS-CoV-2, using saliva specimens for the detection of SARS-CoV-2 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.04.2023 | ||
| 500 | |a Date Revised 18.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights reserved. | ||
| 520 | |a BACKGROUND: In the context of the coronavirus disease 2019 (COVID-19) pandemic, a rapid and reliable point-of-care test is an essential tool for controlling the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In particular, an immunochromatography test (ICT) that uses saliva specimens for rapid antigen detection not only reduces the risk of secondary infections but also reduces the burden on medical personnel | ||
| 520 | |a METHODS: The newly developed salivary antigen test kit "Inspecter Kowa® SARS-CoV-2" is an ICT to which saliva specimens can be directly applied. We evaluated its usefulness in comparison with reverse transcription quantitative PCR (RT-qPCR) and the Espline® SARS-CoV-2 Kit for the detection of SARS-CoV-2 using nasopharyngeal swab specimens. In this study, 140 patients with suspected symptomatic COVID-19 who visited our hospital were enrolled, and nasopharyngeal swab and saliva specimens were collected after they consented to participate in the study | ||
| 520 | |a RESULTS: Inspector Kowa SARS-CoV-2 was positive in 45 of 61 (73.8%) saliva that were positive by RT-qPCR and the Espline® SARS-CoV-2 Kit was also positive in 56 of 60 (93.3%) Np swabs that were positive by RT-qPCR. Good antigen detection was achieved by ICT with saliva and nasopharyngeal swab specimens when viral load was ≥105 copies/mL, whereas detection sensitivity was low when viral load was <105 copies/mL, especially in saliva specimens | ||
| 520 | |a CONCLUSION: This ICT for the detection of SARS-CoV-2 salivary antigen is an attractive tool that does not require specialized equipment and allows patients to perform the entire process from sample collection to self-diagnose and to reduce the burden on medical care during a pandemic | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Antigen detection | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Immunochromatography | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Saliva | |
| 700 | 1 | |a Orihara, Yuta |e verfasserin |4 aut | |
| 700 | 1 | |a Tezuka, Mariko |e verfasserin |4 aut | |
| 700 | 1 | |a Takahashi, Rina |e verfasserin |4 aut | |
| 700 | 1 | |a Noguchi, Sakiko |e verfasserin |4 aut | |
| 700 | 1 | |a Matsuzaki, Nanako |e verfasserin |4 aut | |
| 700 | 1 | |a Takada, Tomohito |e verfasserin |4 aut | |
| 700 | 1 | |a Kobari, Naomi |e verfasserin |4 aut | |
| 700 | 1 | |a Ogane, Kana |e verfasserin |4 aut | |
| 700 | 1 | |a Kawamura, Rieko |e verfasserin |4 aut | |
| 700 | 1 | |a Kawamura, Toru |e verfasserin |4 aut | |
| 700 | 1 | |a Takeuchi, Shinichi |e verfasserin |4 aut | |
| 700 | 1 | |a Kamiyama, Yuki |e verfasserin |4 aut | |
| 700 | 1 | |a Shiomi, Rie |e verfasserin |4 aut | |
| 700 | 1 | |a Aoyagi, Ryutaro |e verfasserin |4 aut | |
| 700 | 1 | |a Saito, Masaya |e verfasserin |4 aut | |
| 700 | 1 | |a Kusano, Takeru |e verfasserin |4 aut | |
| 700 | 1 | |a Nakaya, Nobuaki |e verfasserin |4 aut | |
| 700 | 1 | |a Kaneko, Satoru |e verfasserin |4 aut | |
| 700 | 1 | |a Morita, Hideo |e verfasserin |4 aut | |
| 700 | 1 | |a Uchida, Yoshihito |e verfasserin |4 aut | |
| 700 | 1 | |a Yazawa, Hiroaki |e verfasserin |4 aut | |
| 700 | 1 | |a Sekiya, Ryu |e verfasserin |4 aut | |
| 700 | 1 | |a Katayama, Kazuki |e verfasserin |4 aut | |
| 700 | 1 | |a Mikami, Shingo |e verfasserin |4 aut | |
| 700 | 1 | |a Sato, Tomoya |e verfasserin |4 aut | |
| 700 | 1 | |a Tarumoto, Norihito |e verfasserin |4 aut | |
| 700 | 1 | |a Kobayashi, Takehito |e verfasserin |4 aut | |
| 700 | 1 | |a Nakamoto, Hidetomo |e verfasserin |4 aut | |
| 700 | 1 | |a Maeda, Takuya |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy |d 1996 |g 29(2023), 6 vom: 01. Juni, Seite 586-591 |w (DE-627)NLM095488073 |x 1437-7780 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2023 |g number:6 |g day:01 |g month:06 |g pages:586-591 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jiac.2023.02.011 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2023 |e 6 |b 01 |c 06 |h 586-591 | ||